INTRODUCTION
Gastrointestinal (GI) disorders, such as irritable bowel syndrome (IBS), are usually non-life-threatening conditions. Even though they generally do not require surgery and do not result in increased mortality, these conditions can cause health problems with serious impairments on a patient's quality of life (QoL) [1] . In fact, the general health status of American and British patients with IBS is worse compared to that of the general population in each country [2] . For instance, young American adults with IBS had a significant reduction in health-related QoL, as evidenced by lower scores on the SF-36 survey compared to the US population [2] . A systematic review of IBS patients concluded that those who respond to therapy have a corresponding improvement in health-related QoL [3] . For example, GI medications, such as Alosetron and Mebeverine, significantly improve symptoms and QoL compared to placebo [4] [5] [6] [7] [8] . These data support the view that symptoms and disability related to GI disorders correlate with QoL, suggesting that those who respond to therapy have an improvement in QoL. * We have no financial disclosures to report regarding the conduct of this research.
The decrease in QoL measures also equates to an eco-nomic burden on the workplace and healthcare system. IBS is one of the most frequently diagnosed GI disorders in primary care and gastroenterology practices [9] . It affects 3% -20% of the US population with women affected twice as much as men, and the peak incidence is between 15 and 34 years of age [10, 11] . The total indirect and direct cost of IBS is estimated to be $30 billion annually, which is higher than that for other chronic conditions such as asthma. Patients with IBS have a tendency to seek medical care for non-GI symptoms more often than individuals without IBS [9] .
Currently, recommendations of the American College of Gastroenterology and the British Society of Gastroenterology for the treatment of functional GI disorders include an initial step (i.e., diagnosis) followed by three secondary steps that involve pharmacological treatment (i.e., antidepressants, antispasmodics, and other medications that affect bowel movement like anti-diarrheals), psychological evaluation, and lifestyle/dietary modifications. Dietary or medical nutrition therapy is usually an integral part of the approach to treat these conditions, since the symptoms of GI disorders are typically subsequent to food ingestion. Thus, a diet that eliminates intolerant foods is usually beneficial for the patient. However, detecting intolerant foods usually requires a patient to record food intake and any symptoms associated with food ingestion, which may be impractical and inconvenient. Therefore, a clinical test detecting intolerant foods can represent a more efficient approach.
IBS and similar GI disorders may be low-grade inflammatory bowel diseases with altered immune activation. Efforts to test for food intolerance in patients with functional GI disorders have focused on the Immunoglobulin E (IgE)-mediated food allergy response, but this immediate-type reaction seems to be rare [12] [13] [14] . Therefore, adverse reactions to food observed in patients with functional GI disorders may be due to a delayed immunological response involving Immunoglobulin G (IgG) antibodies, which are reported to be causal in several food hypersensitivities [15] [16] [17] [18] . The ImmunoBloodprint is a novel food sensitivity test that detects the presence of IgG antibodies to specific foods.
We hypothesized that an individualized elimination diet based on the IgG-reactive foods detected by the ImmunoBloodprint would improve QoL and GI-specific symptoms in patients with self-reported GI disorders. Therefore, the purpose of this study was to evaluate changes in health-related QoL, as assessed by the Irritable Bowel Syndrome-36 (IBS-36) and the Medical Outcomes Study Short Form-36 (SF-36) surveys in patients with unresolved self-reported GI disorders following an immunologically-reactive food elimination diet based on the ImmunoBloodprint results.
METHODS

Subjects
Potential subjects (n = 84) who self-reported an unresolved GI disorder lasting more than 6 months, e.g., IBS, diarrhea, constipation, gas, or bloating, were identified through referrals and advertisements at the University of Miami Miller School of Medicine between 2008 and 2010. The study was conducted with the approval of the Institutional Review Board for human subjects research, and all participants signed informed consent and HIPAA forms before commencing in the study. The sample was comprised of 18% males (n = 15) and 82% females (n = 69) with a mean age of 45.6 years (SD = 12.8; R = 19, 68). The racial/ethnic distribution of the sample was as follows: 48.1% Hispanic (n = 37), 44.2% white, nonHispanic (n = 34), 6.5% black, non-Hispanic (n = 5), and 1.3% other groups (n = 1).
Study Design
Subjects were enrolled in the study if they were: 1) older than 18 years of age; 2) not currently participating in another research trial for GI problems; 3) not suffering from serious medical complications that might limit their participation, such as recent heart attack, stroke, or chronic kidney disease; 4) not pregnant; and/or 5) willing to eliminate the reactive foods from their diet for 90 days based on the results of the ImmunoBloodprint test.
Each eligible subject was scheduled for a blood draw, and the blood sample was sent to Immuno Laboratories, Inc. (Ft. Lauderdale, FL) for processing and analysis. Immuno Laboratories, Inc. is accredited by the College of American Pathologists, licensed federally and in several states, and utilizes a proprietary test known as the ImmunoBloodprint. The ImmunoBloodprint test uses microtiter plates with tiny wells that hold antigens of 115 commonly eaten foods and ingredients (see Appendix 1). The blood is tested with each antigen. Laser-like light beamed on a micro plate reads precisely which foods are reactive to each participant's blood based on IgG responses to each antigen.
Subjects were provided with both the test results and an individualized dietary plan based on replacing IgGreactive foods with non-reactive foods as per the ImmunoBloodprint results, when they returned to complete the baseline assessment. A personalized rotation plan of their non-reactive foods and general information about healthy eating, food preparation, and shopping were given to all participants. No other behaviors were addressed in the instructions. Primarily, participants were advised to focus as much as possible on eliminating their reactive foods from the diet for the entire 90-day period. All participants were encouraged to contact the study team with any dietary related questions.
Outcomes and Assessment Schedule
Each participant completed a basic demographics and medical history questionnaire at baseline and recorded any changes in their medications during the course of the study. Criteria used to select the assessment instruments included: 1) appropriateness for the population; 2) ease of administration and scoring; 3) experience administering these measures, and 4) employment of measures involving a multi-method (i.e., self-report and physical measures) approach to enhance the validity of the overall assessment.
The primary outcome of this study was QoL, as measured by the IBS-36 [19] and the SF-36 [20] . The IBS-36 has high test-retest reliability, internal consistency, content validity, convergent and divergent construct validities, sensitivity to changes in symptom severity, and high correlation with the SF-36 [19] . This test also queries multiple symptoms for persons suffering from GI disorders and is highly correlated with patient-reported symptoms [19] . The IBS-36 provides one total score (possible range of 0 -216) with a lower score indicating a better QoL. The SF-36 provides psychometrically-based physical and mental health summary measures and a preference-based health utility index. The SF-36 includes a t-score for each scale or domain ranging from 0 -100 with higher scores representing better perceived QoL. The SF-36 is a general QoL measure that is commonly used, but it does not address areas of concern for patients with GI disorders, like food avoidance and bowel-specific problems [19] . It also does not target a specific age, disease, or treatment group [20] .
Subjects were instructed on how to complete a 3-day food record (two weekdays and one weekend day to allow for fluctuations over a normal weekly period) at each assessment in order to list all food and beverage consumption during that particular time. The 3-day food record was used at each assessment to gauge compliance to the elimination diet based on a comparison of the foods eaten during those three days to the ImmunoBloodprint results of reactive foods for that subject. For example, if a subject ate 20 different foods during the 3-day period and one of the foods was IgG-reactive according to the ImmunoBloodprint results, then the subject was 95% compliant with the diet for that particular assessment. Subjects were assessed at baseline and 30-, 60-, and 90-day follow-up.
Statistical Analysis
Data were analyzed using SPSS 19 (IBM Inc., Chicago, IL) for Windows. Frequency and descriptive statistics were calculated on all variables. We utilized linear mixed modeling (LMM) to assess the fixed effect of time on changes in our outcome variables from baseline to the 90-day follow-up period. If the type III test of the fixed effect of time and the parameter estimate of the baseline to the 90-day fixed effect were significant, then we used pairwise comparisons to determine the unique differences between baseline and follow-up values at 30, 60, and 90 days. LMM allowed us to account for subject attrition, inter-correlated responses between time points, and non-constant variability. The criterion for statistical significance was α = 0.05.
RESULTS
Prevalence of IgG-Reactive Foods
For all participants, the average number of IgG-reactive foods and ingredients was 14.3 (SD = 6.2, R = 5, 31). Average percent compliance to the diet was as follows: 30-day follow-up, 95.8% (SD = 6.6, R = 76.92, 100); 60-day follow-up, 95.8% (SD = 7.4, R = 71.4, 100); and 90-day follow-up, 95.5% (SD = 5.2, R = 85.7, 100). Figure 1 shows the top 10 most frequently tested IgGreactive foods and ingredients for all participants. 
Quality of Life
DISCUSSION
In this clinic-based study of persons with unresolved GI disorders, we assessed the effect of an IgG-mediated food sensitivity test, the ImmunoBloodprint, combined with a subsequent elimination diet for 90 days on QoL. Eliminating foods to which participants were sensitive, as identified by the IgG-mediated ImmunoBloodprint test, resulted in clinically-significant improvement in QoL, as measured by the IBS-36 and the SF-36. The changes found on the IBS-36 and SF-36 in our study suggest that not only were our participants making improvements, but they were subjectively associating those changes with how they felt in multiple domains. Additionally, the use of self-report QoL instruments to assess GI disorders is increasing, given that the patient's perspective is critical in any health condition [21] . The reported increase in QoL may equate to increased productivity, less absentteeism from work, less utilization of medical specialists, and an overall reduction on the economic burden of this disease. Although IgE testing is the most commonly recognized method to determine food hypersensitivity [22, 23] , the use of IgG testing may also be useful in identifying foods that are reactive [21, 24] . Despite their potential usefulness as a clinical tool, the medical community does not universally accept the use of IgG-mediated testing since IgG has been found in healthy individuals after ingestion of foods [25] [26] [27] . In addition, it is unknown what percentage of the population with high levels of IgG food-related antibodies has unhealthy bowel symptoms. Furthermore, inter-laboratory reproducibility is lacking, and the sensitivity and specificity of IgG food hypersensitivity testing need to be evaluated [21] .
Nonetheless, this study demonstrates that eliminating foods that are IgG-reactive, while replacing them with similar, non-reactive foods to prevent nutrient deficiencies, can be a novel strategy for improving QoL in patients with unresolved GI disorders. It is possible that QoL is improved by reducing symptomatology like abnormal colonic motility manifested by more frequent and stronger bowel contractions and shorter colonic transit time that may be explained by IgG sensitivity exhibited to certain foods. This method is a relatively low-cost strategy that may be useful when combined with other existing approaches to the illness. Food exclusion diets require strict adherence, changing eating patterns, selfdiscipline, will-power, and motivation, but the reported high compliance to the diet (>95% average compliance) in our study demonstrates their feasibility. Our high compliance rate may have been due to test results guiding the food elimination diet [28] , instead of trial and error, and/ or immediate positive response as seen in self-reported QoL. Therefore, IgE and IgG food testing can help direct the food exclusion diet initially; however, the only modality for truly identifying a clinical reaction to foods is through oral food challenge [29, 30] .
Food challenge follows an elimination diet by adding back to the diet the potentially reactive foods. Once the offending foods have been identified, they may be restored to the diet on a rotation schedule of 3 -4 days between ingestion. This rotation method is utilized to prevent GI symptom reoccurrence, which occurs by possible accumulation of antibody-antigen complexes due to reactive foods eaten on successive days [21] . Even though our study did not employ food challenge after the elimination diet, as other studies have [21, 24] , our results provide evidence that the ImmunoBloodprint could be effective in guiding exclusion diets for this purpose. Studies employing blinded food challenges are also necessary to corroborate IgG testing results and thus aid in overcomeing the bias against this potentially useful tool. Hence, further studies are warranted in which the ImmunoBloodprint test is used to guide exclusion diets and food challenges.
LIMITATIONS
Limitations of this study include our lack of any additional biological markers of inflammation, e.g., C-reactive protein, cytokines, or growth factors, to be able to determine the possible relationship between changes in QoL with indicators of chronic inflammation. For example, the decreased release of inflammatory mediators, like cytokines and lymphocyte proliferation responses, can be measured after food elimination diets [31, 32] . Some studies have suggested the need to evaluate histamine, substance P, and serotonin production as other key biological indicators [21] . Another limitation of this study is the lack of a control group of participants with unresolved GI disorders on a "sham" diet. Previous food elimination diets have reported that patients on sham diets also improved to a lesser extent in QoL measures, highlighting the importance of performing double-blind, randomized controlled trials in order to prevent overestimation of the potential benefit of the intervention [21] . Participants were not re-assessed with another IgG test at 90 days to determine consistency across the study and/or to denote any changes in response to the intervention. Lastly, we included participants who self-reported GI disorders and were not diagnosed by ROME criteria for functional GI disorders. However, most patients with GI disorders, including IBS, are undiagnosed [9] , making it difficult to entirely delineate the population characteristics. While this may call into question the direct clinical relevance of our findings to a more standardized population, our study sample included twice as many females as males, which is similar to the IBS population.
CONCLUSION
The results of our study suggest that utilizing an elimination diet of IgG-reactive foods, detected with the Im-munoBloodprint test, in participants with unresolved self-reported GI disorders improves QoL measures. Thus, this trial demonstrated that IgG-mediated testing combined with a subsequent elimination diet may offer the opportunity for such patients to improve their dietary behaviors and symptoms by utilizing a tailored, individually-specific program. This dietary strategy, offering considerable benefit to patients with GI disorders as shown in this and previous studies [28] , can represent a tool worthy of further clinical and biomedical research. Future research should focus on randomized controlled trials using double-blind methods and patients identified with ROME criteria. Additional studies are necessary to explore the correlation between IgG food sensitivity and abnormalities in colonic motility. Finally, future analyses may determine if improved patient QoL scores translate into reduced cost of IBS to the patient, employer, and the overall healthcare system.
